Emerging retatrutide, a dual -action drug targeting simultaneously GLP-1 and GIP receptors, is generating considerable buzz within the healthcare community. Preliminary clinical studies have shown significant decreases in body size and advancements in metabolic markers for people with obesity . Researchers believe this novel approach may signify a